Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01950663 · ClinicalTrials.gov registry record · NA

RETeval Study for Diabetic Retinopathy

A NA study of Diabetic Retinopathy, sponsored by Inoveon Corporation.

Completed
Registry status
NA
Development phase
468
Enrollment target
2
Study locations

NCT01950663 is a NA study of Diabetic Retinopathy that has completed, run by Inoveon Corporation. The registered enrollment target is 468 participants, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01950663, a NA study of Diabetic Retinopathy, has completed, sponsored by Inoveon Corporation.

COMPLETED
Registry status
NA
Development phase
468 participants
Enrollment target
2
Study locations

Study Summary

RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy. The purpose of this study is to calibrate RETeval, and then measure its ability to detect vision threatening diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field, dilated, stereo, color fundus photography, read according to the ETDRS protocol, will be used as the gold standard.

Conditions Studied

Interventions

  • DEVICE RETeval

Study Locations (2)

Georgia

  • Atlanta VA Medical Center - Decatur

Oklahoma

  • Oklahoma City VA Medical Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 468 participants
Start Date 2013-09
Est. Completion 2014-04
Phase NA

Sponsor

Inoveon Corporation

1 total trials

What the Registry Record Tells You About NCT01950663

The ClinicalTrials.gov registry entry for NCT01950663 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (72% lower). The listed sponsor is Inoveon Corporation, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which RETeval is the first listed.

NCT01950663 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT01950663 about?

NCT01950663 is a clinical study titled "RETeval Study for Diabetic Retinopathy". RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy. The purpose of this study is to calibrate RETeval, and then measure its ability to detect vision threatening diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field, dilated, stereo,...

What is the current status of trial NCT01950663?

This trial is currently completed. It is a NA study. The enrollment target is 468 participants. The study started on 2013-09. Estimated completion is 2014-04.

What conditions does trial NCT01950663 study?

This clinical trial studies the following conditions: Diabetic Retinopathy.

What interventions are being tested in trial NCT01950663?

The interventions under investigation include: RETeval (DEVICE).

Who is sponsoring clinical trial NCT01950663?

This trial is sponsored by Inoveon Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01950663 being conducted?

This trial has 2 study locations across Georgia, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Retinopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.